# OnCo record eortc-22991 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/eortc-22991/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "eortc-22991", "NCT00021450" ;
  schema:name "EORTC 22991"@en ;
  schema:alternateName "EORTC 22991"@en ;
  schema:description "Six months of hormone therapy added to modern dose-escalated radiotherapy roughly halves the chance the PSA comes back, at every radiation dose tested."@en ;
  schema:url <https://onco.cc/trials/eortc-22991/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00021450>, <https://doi.org/10.1200/JCO.2015.64.8055> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:companies <https://onco.cc/companies/curie-nki-eortc/> ;
  onco:terms <https://onco.cc/terms/adt/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/biochemical-recurrence/> ;
  onco:trials <https://onco.cc/trials/rtog-9408/>, <https://onco.cc/trials/dart-01-05-gicor/>, <https://onco.cc/trials/eortc-22863/> .